The Becker Muscular Dystrophy drugs in development market research report provides comprehensive information on the therapeutics under development for Becker Muscular Dystrophy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Becker Muscular Dystrophy. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Becker Muscular Dystrophy and features dormant and discontinued products.

GlobalData tracks 11 drugs in development for Becker Muscular Dystrophy by 11 companies/universities/institutes. The top development phase for Becker Muscular Dystrophy is preclinical with five drugs in that stage. The Becker Muscular Dystrophy pipeline has 11 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Becker Muscular Dystrophy pipeline products market are: SOM Biotech, Italfarmaco and Epirium Bio.

The key targets in the Becker Muscular Dystrophy pipeline products market include Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98), Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98), and Dysferlin (Dystrophy Associated Fer 1 Like Protein or Fer 1 Like Protein 1 or DYSF).

The key mechanisms of action in the Becker Muscular Dystrophy pipeline product include Glucocorticoid Receptor (GR or Nuclear Receptor Subfamily 3 Group C Member 1 or NR3C1) Agonist with one drug in Phase II. The Becker Muscular Dystrophy pipeline products include four routes of administration with the top ROA being Oral and five key molecule types in the Becker Muscular Dystrophy pipeline products market including Small Molecule, and Recombinant Protein.

Becker Muscular Dystrophy overview

Becker muscular dystrophy (BMD) is one of type of muscular dystrophy, a group of genetic, degenerative diseases primarily affecting voluntary muscles. Symptoms include pain and sensation; difficulty with running, hopping, and jumping; toe walking; breathing problems; cognitive problems; and frequent falls.

For a complete picture of Becker Muscular Dystrophy’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.